Dr. Swain on the Impact of Chemotherapy on Outcomes in HER2-Positive Metastatic Breast Cancer
October 15th 2014Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses a taxane's impact on outcomes in patients with HER2-positive metastatic breast cancer.
Read More
Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study
September 28th 2014Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Read More